Abstract
Background: Adult-type granulosa cell tumors (AGCT) are an uncommon ovarian cancer subtype. We used spatial transcriptomics to explore gene expression in tumor versus adjacent stromal cells within the tumor microenvironment (TME), and in primary versus recurrent tumors.
Methods: Four unmatched FFPE AGCT samples (two primary, two recurrent) were processed on the 10X Genomics Visium platform. Seurat clusters and STdeconvolution topics were annotated, followed by pathway enrichment and TME assessment by functional gene signatures. Primary and recurrent tumors were compared using pseudobulk and DESeq2. Tumor-stromal interactions were analyzed with SpatialCellChat, and trajectories with Monocle.
Results: Granulosa cells and fibroblasts were the most common cell types. These were subclassified into proliferative and steroidogenic granulosa cells, and myofibroblastic (myCAF), extracellular matrix (ECM-CAF), inflammatory (iCAF), and perivascular fibroblasts. MAPK, PI3K, and KRAS signaling were the most frequently enriched pathways. The TME was fibrotic and dominated by cancer-associated fibroblasts. SpatialCellChat highlighted the importance of the extracellular matrix and showed bidirectional tumor-stroma signaling. In total, 122 genes were upregulated in primary tumors and 33 were differentially expressed in recurrent tumors, including the steroidogenic enzyme CYP19A1, the receptor tyrosine kinases ERBB4 and RASGRF1, and stromal remodeling genes.
Conclusion: Spatial transcriptomics demonstrates hormonally active tumor regions and a fibrotic, CAF-dominant tumor microenvironment in AGCT. Several findings with potential translational significance could warrant further investigation.
Keywords
References
-
3. Homesley HD, Bundy BN, Hurteau JA, Roth LM. Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: A gynecologic oncology group study. Gynecol Oncol. 1999;72(2):131-137.[DOI]
-
4. Brown J, Shvartsman HS, Deavers MT, Ramondetta LM, Burke TW, Munsell MF, et al. The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors. Gynecol Oncol. 2005;97(2):489-496.[DOI]
-
5. Burton ER, Brady M, Homesley HD, Rose PG, Nakamura T, Kesterson JP, et al. A phase II study of paclitaxel for the treatment of ovarian stromal tumors: An NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol. 2016;140(1):48-52.[DOI]
-
7. Ray-Coquard I, Harter P, Lorusso D, Dalban C, Vergote I, Fujiwara K, et al. Effect of weekly paclitaxel with or without bevacizumab on progression-free rate among patients with relapsed ovarian sex cord-stromal tumors: The ALIENOR/ENGOT-ov7 randomized clinical trial. JAMA Oncol. 2020;6(12):1923-1930.
-
8. Banerjee SN, Tang M, O’Connell RL, Sjoquist K, Clamp AR, Millan D, et al. A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: The PARAGON/ANZGOG 0903 trial. Gynecol Oncol. 2021;163(1):72-78.
-
9. Garcia-Donas J, Garrigos L, Lainez N, Santaballa A, Redondo A, Cueva JF, et al. Open-label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced non-resectable granulosa cell ovarian tumors: The Greko II study (GETHI2013-01). Clin Transl Oncol. 2025;27(7):3223-3231.
-
11. Shah SP, Köbel M, Senz J, Morin RD, Clarke BA, Wiegand KC, et al. Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med. 2009;360(26):2719-2729.[DOI]
-
14. Carles A, Trigo-Gonzalez G, Cao Q, Cheng SWG, Moksa M, Bilenky M, et al. The pathognomonic FOXL2 C134W mutation alters DNA-binding specificity. Cancer Res. 2020;80(17):3480-3491.[DOI]
-
17. Khlebus EY, Vuttaradhi VK, Ferri-Borgogno S, Brodsky AL, Lawson BC, Mok SC, et al. Multiplexed imaging mass cytometry reveals tumor-immune microenvironment-dependent hormone receptor expression in adult-type ovarian granulosa cell tumors. Cancer Res Commun. 2025;5(10):1894-1909.
-
24. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550.[DOI]
-
26. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene Ontology: Tool for the unification of biology. Nat Genet. 2000;25(1):25-29.[DOI]
-
29. Liberzon A, Birger C, Thorvaldsdóttir H, Ghandi M, Mesirov JP, Tamayo P. The molecular signatures database hallmark gene set collection. Cell Syst. 2015;1(6):417-425.[DOI]
Copyright
© The Author(s) 2026. This is an Open Access article licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Publisher’s Note
Share And Cite


